Leukemia, Myelomonocytic, Juvenile clinical trials

The registry lists 125 studies for Leukemia, Myelomonocytic, Juvenile across more than 10 countries. 13 are recruiting or about to start. 10 of them are mainly about Leukemia, Myelomonocytic, Juvenile (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Leukemia, Myelomonocytic, Juvenile studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 73
Terminated: 19
Recruiting: 12
Active, not recruiting: 8
Status unknown: 7
Withdrawn: 5

Phase

Phase 2: 56
Phase 1: 35
Phase 3: 12
Phase 4: 1

Where

United States: 108
Canada: 14
Australia: 8
Italy: 5
Germany: 5
Puerto Rico: 4

Who runs them

Fred Hutchinson Cancer Center (19) · St. Jude Children's Research Hospital (11) · Children's Oncology Group (11) · Masonic Cancer Center, University of Minnesota (7) · University of California, San Francisco (5) · National Cancer Institute (NCI) (5) · Case Comprehensive Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4)

What is being tested here

Drugs under test in Leukemia, Myelomonocytic, Juvenile studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	All
Fludarabine	2	22
Cyclophosphamide	1	18
Busulfan	1	15
Melphalan	1	11
Cytarabine	1	6
Azacitidine	1	5
Trametinib	1	2
Thymoglobulin	1	2
Imetelstat	1	1
Fludarabine phosphate	0	16

Drug classes tested here Antimetabolites 3 open · Alkylating agents 1 open · Calcineurin inhibitors 12 · Corticosteroids 6 · Tyrosine kinase inhibitors (TKIs) 4

Coming up

1phase 3 study under way

8studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8

Dec 2026A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation · Dana-Farber Cancer Institute
May 2027Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases · University of Florida
Jun 2027Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · Masonic Cancer Center, University of Minnesota
Jul 2027CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT · Children's Hospital of Philadelphia
Jul 2027Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation · Johns Hopkins All Children's Hospital
Oct 2027HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant · Fred Hutchinson Cancer Center
Oct 2027Myeloproliferative Neoplasms (MPNs) Patient Registry · University Health Network, Toronto
Nov 2027MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies · Masonic Cancer Center, University of Minnesota

Who these studies take

Of the 12 Leukemia, Myelomonocytic, Juvenile studies recruiting now, 3 (25%) set no upper age limit and 8 (67%) stop at 75 or younger. 11 (92%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 12
Age	Women	Men
10	10 (83%)	10 (83%)
18	11 (92%)	11 (92%)
30	7 (58%)	7 (58%)
40	6 (50%)	6 (50%)
50	6 (50%)	6 (50%)
65	4 (33%)	4 (33%)
75	4 (33%)	4 (33%)
85	3 (25%)	3 (25%)

Across all 125 studies, recruiting or not: 71% stop at 75 or younger and 61% at 65; 91% take children; 0% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myelomonocytic, Juvenile studies take

Of 17 phase 2 interventional studies under Leukemia, Myelomonocytic, Juvenile, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	64 mo39–107 · 17 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Results posted1

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsOct 15, 2026NCT05656248

Studies

Recruiting first, then most recently updated. Showing 50 of 125. Browse all 125 → or search them.